Journal
PHARMACEUTICS
Volume 15, Issue 5, Pages -Publisher
MDPI
DOI: 10.3390/pharmaceutics15051533
Keywords
snake venoms; mitochondrial bioenergetics; oxidative phosphorylation; GPVI antagonist; BH3 mimetics; Venetoclax
Categories
Ask authors/readers for more resources
We have described toxins derived from the venom of Bothrops pictus snake that inhibit platelet aggregation and cancer cell migration. We characterized a novel P-III class snake venom metalloproteinase called pictolysin-III (Pic-III), which hydrolyzes various proteins and is affected by different ions and inhibitors. Pic-III also affects mitochondrial bioenergetics in cells and increases sensitivity to a cytotoxic drug in cancer cells.
From the venom of the Bothrops pictus snake, an endemic species from Peru, we recently have described toxins that inhibited platelet aggregation and cancer cell migration. In this work, we characterize a novel P-III class snake venom metalloproteinase, called pictolysin-III (Pic-III). It is a 62 kDa proteinase that hydrolyzes dimethyl casein, azocasein, gelatin, fibrinogen, and fibrin. The cations Mg2+ and Ca2+ enhanced its enzymatic activity, whereas Zn2+ inhibited it. In addition, EDTA and marimastat were also effective inhibitors. The amino acid sequence deduced from cDNA shows a multidomain structure that includes a proprotein, metalloproteinase, disintegrin-like, and cysteine-rich domains. Additionally, Pic-III reduces the convulxin- and thrombin-stimulated platelet aggregation and in vivo, it has hemorrhagic activity (DHM = 0.3 mu g). In epithelial cell lines (MDAMB-231 and Caco-2) and RMF-621 fibroblast, it triggers morphological changes that are accompanied by a decrease in mitochondrial respiration, glycolysis, and ATP levels, and an increase in NAD(P)H, mitochondrial ROS, and cytokine secretion. Moreover, Pic-III sensitizes to the cytotoxic BH3 mimetic drug ABT-199 (Venetoclax) in MDA-MB-231 cells. To our knowledge, Pic-III is the first SVMP reported with action on mitochondrial bioenergetics and may offer novel opportunities for promising lead compounds that inhibit platelet aggregation or ECM-cancer-cell interactions.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available